サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1544039

狭心症治療薬の世界市場

Angina Pectoris Drugs

出版日
ページ情報
英文 196 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
狭心症治療薬の世界市場
出版日: 2024年08月29日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 196 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

狭心症治療薬の世界市場は2030年までに197億米ドルに達する見込み

2023年に145億米ドルと推定される狭心症治療薬の世界市場は、2023年から2030年にかけてCAGR 4.5%で成長し、2030年には197億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるβ遮断薬は、CAGR 4.9%を記録し、分析期間終了時には96億米ドルに達すると予測されます。カルシウム拮抗薬セグメントの成長率は、分析期間中CAGR 4.3%と推定されます。

米国市場は40億米ドルと推定、中国はCAGR 4.3%で成長予測

米国の狭心症治療薬市場は2023年に40億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに31億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは4.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.2%と3.7%と予測されています。欧州では、ドイツがCAGR 4.4%で成長すると予測されています。

世界の狭心症治療薬市場- 主要動向と促進要因のまとめ

狭心症治療薬が心血管治療に欠かせない理由とは？

狭心症は、心臓への血流が減少することによる胸痛を特徴とする疾患で、心血管治療における重要な懸念事項であり続けています。狭心症の効果的な管理は、患者の予後を改善し、より重篤な心イベントを予防するために不可欠です。硝酸薬、β遮断薬、カルシウム拮抗薬、抗血小板薬などの狭心症治療薬は、症状を緩和し、QOLを高め、心臓発作のリスクを軽減する上で重要な役割を果たしています。これらの薬剤は、錠剤、カプセル剤、注射剤など様々な剤形があるため、個々の患者のニーズに合わせた治療が可能です。心血管系疾患は世界的に死亡原因の第1位を占めているため、臨床におけるこれらの薬剤の重要性はいくら強調してもしすぎることはありません。

技術の進歩は狭心症治療薬市場にどのような影響を与えているか？

技術の進歩は、市場情勢を大きく変えています。ドラッグフォーミュレーションやドラッグデリバリーシステムにおける技術革新は、医薬品の有効性と安全性を高めています。例えば、徐放性製剤や経皮パッチの開発により、より安定した薬物送達が可能になり、患者の服薬アドヒアランスも向上しています。さらに、特にゲノミクスと個別化医療の分野における製薬研究の進歩は、患者の特定の遺伝的・分子的プロファイルに対処する標的療法への道を開いています。このアプローチは治療結果を改善するだけでなく、副作用を最小限に抑えることもできます。投薬管理や遠隔モニタリングのためのモバイルアプリなどのデジタルヘルスツールの統合は、患者のコンプライアンスをさらに高め、治療計画のリアルタイム調整を可能にします。

なぜ患者中心の治療が狭心症治療戦略の中心なのか？

患者中心の治療は、狭心症治療戦略の礎となりつつあります。ヘルスケアシステムがより個別化された予防的アプローチにシフトするにつれ、治療効果に影響を与える患者固有の因子を理解することが重視されるようになってきています。生活習慣の改善、危険因子の管理、患者教育は包括的な治療計画の不可欠な要素です。ヘルスケアプロバイダーは現在、デジタルツールを活用し、患者の病状についての教育、経過の追跡、服薬のリマインドを行っています。この総合的なアプローチは、患者の転帰を改善するだけでなく、全体的な体験を向上させ、満足度の向上につながります。さらに、患者の服薬アドヒアランスとコンプライアンスを重視することは、狭心症の再発や合併症の予防には一貫した服薬が不可欠であるため、狭心症管理を長期的に成功させる上で極めて重要です。

狭心症治療薬市場の成長を促進する要因は？

狭心症治療薬市場の成長は、技術の進歩、最終用途、進化するヘルスケア慣行に関するいくつかの要因によって牽引されています。心血管疾患の有病率の増加と世界人口の高齢化は、狭心症の発生率が年齢とともに上昇するため、市場拡大の主な要因となっています。より効果的で安全な製剤の開発など、医薬品開発における技術革新が新たな治療の採用を後押ししています。バイオマーカー研究の進歩に支えられた個別化医療の動向は、狭心症の標的治療のビジネスケースを強化しています。さらに、デジタルヘルスツールの治療計画への統合は、包括的な管理ソリューションへの需要を生み出しています。ヘルスケア支出の増加と保険適用範囲の改善は、これらの薬剤へのアクセスをさらに促進しています。さらに、心血管系の予防医療への関心の高まりと外来治療へのシフトが、狭心症治療薬の対応可能な市場を拡大しています。これらの要因が総合的に狭心症治療薬市場の力強い成長を後押しし、革新的で効果的な治療ソリューションへの継続的なニーズを浮き彫りにしています。

調査対象企業の例（注目の46社）

  • Amgen, Inc.
  • Bayer AG
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Sanofi SA

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP10288

Global Angina Pectoris Drugs Market to Reach US$19.7 Billion by 2030

The global market for Angina Pectoris Drugs estimated at US$14.5 Billion in the year 2023, is expected to reach US$19.7 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2023-2030. Beta Blockers, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$9.6 Billion by the end of the analysis period. Growth in the Calcium Channel Blockers segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.0 Billion While China is Forecast to Grow at 4.3% CAGR

The Angina Pectoris Drugs market in the U.S. is estimated at US$4.0 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$3.1 Billion by the year 2030 trailing a CAGR of 4.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.2% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Global Angina Pectoris Drugs Market - Key Trends and Drivers Summarized

Why Are Angina Pectoris Drugs Vital in Cardiovascular Care?

Angina pectoris, a condition characterized by chest pain due to reduced blood flow to the heart, remains a significant concern in cardiovascular care. Effective management of angina pectoris is critical to improving patient outcomes and preventing more severe cardiac events. Angina pectoris drugs, including nitrates, beta-blockers, calcium channel blockers, and antiplatelet agents, play an essential role in alleviating symptoms, enhancing quality of life, and reducing the risk of heart attacks. The availability of these drugs in various formulations—such as tablets, capsules, and injectables—ensures that treatment can be tailored to individual patient needs. As cardiovascular diseases continue to be the leading cause of mortality globally, the importance of these drugs in clinical practice cannot be overstated.

How Are Technological Advancements Influencing the Angina Pectoris Drugs Market?

Technological advancements are significantly shaping the landscape of the angina pectoris drugs market. Innovations in drug formulation and delivery systems are enhancing the efficacy and safety profiles of these medications. For instance, the development of extended-release formulations and transdermal patches allows for more consistent drug delivery and better patient adherence. Additionally, advancements in pharmaceutical research, particularly in the fields of genomics and personalized medicine, are paving the way for targeted therapies that address the specific genetic and molecular profiles of patients. This approach not only improves treatment outcomes but also minimizes adverse effects. The integration of digital health tools, such as mobile apps for medication management and remote monitoring, further enhances patient compliance and enables real-time adjustments to treatment plans.

Why Is Patient-Centric Care Central to Angina Pectoris Treatment Strategies?

Patient-centric care is increasingly becoming the cornerstone of angina pectoris treatment strategies. As healthcare systems shift towards more personalized and preventive approaches, there is a growing emphasis on understanding patient-specific factors that influence the effectiveness of treatment. Lifestyle modifications, risk factor management, and patient education are integral components of a comprehensive treatment plan. Healthcare providers are now leveraging digital tools to educate patients about their condition, track their progress, and remind them to take their medications. This holistic approach not only improves patient outcomes but also enhances the overall experience, leading to higher satisfaction rates. Moreover, the focus on patient adherence and compliance is critical in ensuring the long-term success of angina pectoris management, as consistent medication use is vital in preventing recurrent episodes and complications.

What Factors Are Driving Growth in the Angina Pectoris Drugs Market?

The growth in the angina pectoris drugs market is driven by several factors related to technological advancements, end-use applications, and evolving healthcare practices. The increasing prevalence of cardiovascular diseases and the aging global population are major contributors to market expansion, as the incidence of angina pectoris rises with age. Technological innovations in drug development, including the creation of more effective and safer formulations, are propelling the adoption of new treatments. The trend towards personalized medicine, supported by advancements in biomarker research, is strengthening the business case for targeted angina pectoris therapies. Additionally, the integration of digital health tools into treatment plans is generating demand for comprehensive management solutions. Rising healthcare expenditure and improved insurance coverage are further facilitating access to these medications. Moreover, the growing focus on preventive cardiovascular care and the shift towards outpatient treatments are expanding the addressable market for angina pectoris drugs. These factors collectively drive the robust growth of the angina pectoris drugs market, highlighting the ongoing need for innovative and effective therapeutic solutions.

Select Competitors (Total 46 Featured) -

  • Amgen, Inc.
  • Bayer AG
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Sanofi SA

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Angina Pectoris Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Prevalence of Cardiovascular Diseases Throws the Spotlight on Angina Pectoris Drugs
    • Advances in Drug Formulation and Delivery Systems Propel Growth in the Angina Pectoris Market
    • Development of Personalized Medicine Strengthens Business Case for Advanced Angina Pectoris Treatments
    • Shift Towards Preventive Cardiovascular Care Impacts the Angina Pectoris Drugs Market
    • Integration of Digital Health Tools in Treatment Plans Generates Demand for Comprehensive Angina Management
    • Trends in Polypharmacy and Combination Therapies Propel Growth in the Angina Pectoris Drugs Market
    • Evolution of Generic Drugs and Biosimilars Expands Addressable Market for Angina Pectoris Medications
    • Advances in Biomarker Research Strengthen Business Case for Targeted Angina Pectoris Treatments
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Angina Pectoris Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Angina Pectoris Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Angina Pectoris Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Beta Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Beta Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Beta Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Calcium Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Calcium Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Calcium Channel Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for ACE Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for ACE Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for ACE Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Nitrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Nitrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Nitrates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Anti-Platelets by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Anti-Platelets by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Anti-Platelets by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Therapeutic Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Therapeutic Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Therapeutic Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Angina Pectoris Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Angina Pectoris Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Angina Pectoris Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • JAPAN
    • Angina Pectoris Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Angina Pectoris Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • CHINA
    • Angina Pectoris Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 32: China Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: China Historic Review for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: China 16-Year Perspective for Angina Pectoris Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • EUROPE
    • Angina Pectoris Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Angina Pectoris Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Europe 16-Year Perspective for Angina Pectoris Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Europe Historic Review for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Europe 16-Year Perspective for Angina Pectoris Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • FRANCE
    • Angina Pectoris Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 41: France Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: France Historic Review for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: France 16-Year Perspective for Angina Pectoris Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • GERMANY
    • Angina Pectoris Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 44: Germany Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Germany Historic Review for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Germany 16-Year Perspective for Angina Pectoris Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 47: Italy Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Italy Historic Review for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Italy 16-Year Perspective for Angina Pectoris Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Angina Pectoris Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 50: UK Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: UK Historic Review for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: UK 16-Year Perspective for Angina Pectoris Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Rest of Europe Historic Review for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Rest of Europe 16-Year Perspective for Angina Pectoris Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Angina Pectoris Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Angina Pectoris Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 59: Rest of World Recent Past, Current & Future Analysis for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Rest of World Historic Review for Angina Pectoris Drugs by Therapeutic Class - Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Rest of World 16-Year Perspective for Angina Pectoris Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Anti-Platelets and Other Therapeutic Classes for the Years 2014, 2024 & 2030

IV. COMPETITION